Hunan Jiudian Pharmaceutical Co Ltd (300705) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Hunan Jiudian Pharmaceutical Co Ltd ¥19.74, price ¥11.11, upside +77.7%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hunan Jiudian Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥8.86 – ¥26.17 · fair‑value band ¥14.79 – ¥24.69 · the ¥11.11 price screens below the ¥19.74 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Hunan Jiudian Pharmaceutical Co in your weekly email
Every Wednesday you see whether Hunan Jiudian Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally.
Show more
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Patch, and Ketoprofen gel patch. The company also offers drugs for analgesic, cardio-cerebrovascular, anti-infection, digestive and urinary system, and breathing and anti-allergy. In addition, it provides CMO/CDMO services. The company was founded in 2001 and is based in Changsha, China.
Stock analysis
Hunan Jiudian Pharmaceutical Co Ltd (300705) currently trades at ¥11.11, while our model-based Fair Value estimate is ¥19.74, implying the stock looks roughly 43.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥27.24 per share, and 11 of the 14 models we run sit above the ¥11.11 price.
Bear case: the Asset-Based group reads lowest at ¥3.56, and 3 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥14.79 (bear) to ¥24.69 (bull), the price of ¥11.11 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hunan Jiudian Pharmaceutical Co Ltd reported revenue of 3.1B CNY in FY2025 versus 1.6B CNY in FY2021, a compound +17.6%/yr. Reported net income was 473M CNY in FY2025, compounding +23.3%/yr from FY2021.
Key figures
Market cap 5.6B CNY (≈ $830M) · P/E ratio 13.7 · P/S ratio 2.08 · EPS (TTM) ¥0.8100 · Dividend yield 3.6% · Net margin 15.2% · Return on equity 14.5% · Return on assets (EBIT) 14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 78%, 300705 screens cheaper than that median.
Fair Value models
Bear ¥14.79Fair Value ¥19.74Bull ¥24.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2999 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
Start year 2020 (pandemic). Over 10 years: +26.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+34.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.4%
Dividend (yield on the price)3.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.30% vs 15%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 19%
Compare Hunan Jiudian Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside+78% · Top 25%
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)13% · Above median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth−15% · Bottom 25%
Dividend yield (TTM)3.6% · Top 25%
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hunan Jiudian Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300705
Frequently asked questions
Is Hunan Jiudian Pharmaceutical Co Ltd (300705) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥19.74 versus a price of ¥11.11, about +78% upside (undervalued).
What is the fair value of 300705?
Our model-based fair value for Hunan Jiudian Pharmaceutical Co Ltd is ¥19.74 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥11.11.
What is the quality score of 300705?
Hunan Jiudian Pharmaceutical Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Our model-based price target is the fair value of ¥19.74 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario ¥14.79, optimistic scenario ¥24.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Hunan Jiudian Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥19.74, about +78% upside versus a price of ¥11.11 (undervalued). Cautious scenario ¥14.79, optimistic scenario ¥24.69. The calculation is refreshed regularly with new filings.
What is the revenue of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Hunan Jiudian Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 3.0B CNY (latest available figure, as of Sep 24, 2026).
Does Hunan Jiudian Pharmaceutical Co Ltd pay a dividend?
Hunan Jiudian Pharmaceutical Co Ltd currently shows a dividend yield of about 3.60% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hunan Jiudian Pharmaceutical Co Ltd it is ¥19.74 per share (as of Sep 24, 2026), against a price of ¥11.11. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Hunan Jiudian Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300705 trades below its calculated fair value: price ¥11.11, fair value ¥19.74, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300705?
No. The price is what the market pays today (¥11.11); the fair value is what the company's own numbers justify (¥19.74). For Hunan Jiudian Pharmaceutical Co Ltd the two are ¥8.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hunan Jiudian Pharmaceutical Co Ltd worth?
The market values Hunan Jiudian Pharmaceutical Co Ltd at about 5.6B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥11.11; our models calculate a fair value of ¥19.74 per share.
What do the bullish and bearish scenarios say about 300705?
Our models span a range for Hunan Jiudian Pharmaceutical Co Ltd: cautious scenario ¥14.79, base ¥19.74, optimistic ¥24.69 per share (as of Sep 24, 2026, price ¥11.11). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300705?
Hunan Jiudian Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 13.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥19.74 is built from several models across several years. Other multiples: P/B 2.1, P/S 1.8, EV/EBITDA 9.4.
How solid is the balance sheet of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Balance-sheet figures for Hunan Jiudian Pharmaceutical Co Ltd (as of Sep 24, 2026): return on equity 14.5%, debt of 0.18 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 300705 from its 52-week high?
Hunan Jiudian Pharmaceutical Co Ltd trades at ¥11.11, about 35% below its 52-week high of ¥16.99 and 17% above the low of ¥9.51 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥19.74 is for.
Which stocks are comparable to Hunan Jiudian Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hunan Jiudian Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥11.11, calculated fair value ¥19.74 (+78%), Quality Score 44/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300705 calculated?
We run Hunan Jiudian Pharmaceutical Co Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥19.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hunan Jiudian Pharmaceutical Co Ltd currently trades 78 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The closing price on Sep 22, 2026 was ¥11.11. Our model-based fair value is ¥19.74, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hunan Jiudian Pharmaceutical Co Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (¥14.79). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Hunan Jiudian Pharmaceutical Co Ltd (300705) come from?
Earnings per share at Hunan Jiudian Pharmaceutical Co Ltd grew +20.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +20.8 %, EBIT margin −0.1 %, tax rate +0.4 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Hunan Jiudian Pharmaceutical Co Ltd
How large is the market capitalisation of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The market capitalisation of Hunan Jiudian Pharmaceutical Co Ltd is 5.6B CNY (≈ $830M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The price-to-sales ratio of Hunan Jiudian Pharmaceutical Co Ltd is 2.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Earnings per share at Hunan Jiudian Pharmaceutical Co Ltd are ¥0.8100 (price ÷ EPS = P/E 13.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The dividend yield of Hunan Jiudian Pharmaceutical Co Ltd is 3.6% (payout 49.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The net margin of Hunan Jiudian Pharmaceutical Co Ltd is 15.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The return on equity (ROE) of Hunan Jiudian Pharmaceutical Co Ltd is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
On an EBIT basis the return on assets of Hunan Jiudian Pharmaceutical Co Ltd is 14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hunan Jiudian Pharmaceutical Co Ltd (300705)?
The operating margin of Hunan Jiudian Pharmaceutical Co Ltd is 11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Revenue at Hunan Jiudian Pharmaceutical Co Ltd is growing −14.5% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hunan Jiudian Pharmaceutical Co Ltd (300705)?
Earnings per share at Hunan Jiudian Pharmaceutical Co Ltd are growing −56.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hunan Jiudian Pharmaceutical Co Ltd (300705) generate?
The free cash flow of Hunan Jiudian Pharmaceutical Co Ltd is −5.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hunan Jiudian Pharmaceutical Co Ltd (300705) carry?
The net debt of Hunan Jiudian Pharmaceutical Co Ltd is 29.0M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hunan Jiudian Pharmaceutical Co Ltd in the live analysis
One click puts Hunan Jiudian Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
